ProCE Banner Activity

Pirtobrutinib Prior to Bispecific Anti-CD20/CD19 CAR T-Cell Therapy in Patients With Relapsed/Refractory Lymphoma

Conference Coverage
Slideset

This analysis from a phase I/II study of LV20.19 CAR T-cell therapy suggests that pirtobrutinib prior to CAR T-cell therapy can be safely used as bridging treatment without adversely affecting CAR T-cell immunophenotype, response, or safety.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi